NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- Major breakthroughs in autism spectrum disorder (ASD) research and policy were featured at ICare4Autism's annual international autism conference which commenced on Monday, June 30th at Hotel Pennsylvania in New York City. Top national and international experts on ASDs discussed medical advances, evidenced-based practices and innovative initiatives in music, movement and technology. The 3-day conference featured Dr. Joshua Weinstein, founder and CEO of ICare4Autism who welcomed hundreds of guests from all over the country and globe, representing autistics, parents, teachers, therapists, behavior analysts, practitioners and researchers. Dr. Weinstein spoke about neuro-diversity and opportunities for autistics in the workplace, and promotion of self advocacy. The ICare4Autism International Autism Conference was dedicated to the Global Autism Workforce Initiative, featuring keynote speaker Randy Lewis, former Senior VP of Walgreens' logistics division, and guest speaker Ari Ne'eman, president of the Autistic Self Advocacy Network. There was a moving musical performance by an inspirational and the talented Christopher Duffley, a blind and autistic 13-year-old who sang "Lean on me" who wowed the audience with his tremendous voice and poise.
ICare4Autism's workforce initiative focuses on promoting innovative programs that integrate autistic individuals into work. Programs that specialize in strengthening the persons' skills needed to succeed at work and easing the transition out of school into employment opportunities that are a good fit for both the employees and employers alike. Monday's conference program discussed the current plans for the Autism Workforce Initiative, as well as what still needs to be done in order to increase awareness about the benefits of having more autistic adults join the workforce worldwide. Dr. Weinstein emphasized the importance of creating new opportunities at this current time, as over 50,000 autistics graduate high school every year. The number of autistic graduates continues to grow, creating a huge need for employment opportunities that will make a difference in their future and our community. He emphasized that many companies are starting to realize how critical it is to implement programs that employ autistics, and are beginning to see that their individual qualities can create a great competitive edge.
Tuesday, July 1st, marked the second day of the conference, focusing on recent scientific advances, drug development efforts, and other medical breakthroughs. Dr. Eric Hollander, chairman of the advisory committee for ICare4Autism, outlined ICare4Autism's mission and goal of collaboration with like minded organizations worldwide and offering help and hope to underserved areas of the world. He indicated that ICare4Autism has programs in over 20 countries, including Pakistan, Ghana, Singapore, and many more. He also presented some of his scientific research, focusing on the effects of oxytocin on chronic and impulsive behaviors.
Other presentations included BCBA workshops in applied behavior analysis. Dr. Gregory Hanley led a very interesting workshop that analyzed functional assessment of problem behavior. He stated that we all should respect why an individual engages in specific actions, and we need to do an open-ended analysis, as opposed to a close-ended, indirect assessment.
At the conference awards dinner Harley Lippman the CEO of Genesis10 was honored with the ... and Jason Maier, Director of the New York office of Stan Johnson Company was give the... award. The conference concluding today was an incredible success, bringing together hundreds of professionals from various aspects of work in autism and families, united in the goal of creating better opportunities for those on the spectrum.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=26800
Autism Community Shares Resources at Autism Conference NEW
Top 10 Most Recent News Articles
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Princess Cruises Launches New Era at Celebration Key
Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market
Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...
Continue ReadingTop 5 Most Recently Viewed Articles
Innovative Scent Dispensing Solution for Hunting Enthusiasts
Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...
Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results
Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...
Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices
Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...
Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today
Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...
Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates
Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...
Continue Reading